TTThai Q. Tran

Thai Q. Tran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thai Q. Tran has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Mei Kong

    Department of Molecular Biology and Biochemistry, Charlie Dunlop School of Biological Sciences, University of California Irvine, Irvine, USA

    3 shared publications
  • Ying Yang

    Department of Molecular Biology and Biochemistry University of California, Irvine Irvine CA USA

    3 shared publications
  • Eric A. Hanse

    Department of Molecular Biology and Biochemistry, Charlie Dunlop School of Biological Sciences, University of California Irvine, Irvine, USA

    2 shared publications
  • Haiqing Li

    Integrative Genomics Core, Department of Shared Resources, Beckman Research Institute, City of Hope, Duarte, USA

    2 shared publications
  • Mari B. Ishak Gabra

    Department of Molecular Biology and Biochemistry; School of Biological Sciences, University of California, Irvine, Irvine, USA

    2 shared publications
  • Xazmin H. Lowman

    Department of Molecular Biology and Biochemistry; School of Biological Sciences, University of California, Irvine, Irvine, USA

    2 shared publications

Latest Publications

  • The B56α subunit of PP2A is necessary for mesenchymal stem cell commitment to adipocyte

    by Eric A Hanse, Min Pan, Wenzhu Liu, Ying Yang, Mari B Ishak Gabra, Thai Q Tran, Xazmin H Lowman, Bryan Ruiz, Qiong A Wang, Mei Kong

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Open Access

    Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth

    by Mari B. Ishak Gabra, Ying Yang, Haiqing Li, Parijat Senapati, Eric A. Hanse, Xazmin H. Lowman, Thai Q. Tran, Lishi Zhang, Linda T. Doan, Xiangdong Xu, et al.

    Tumour cells adapt to nutrient deprivation in vivo, yet strategies targeting the nutrient poor microenvironment remain unexplored. In melanoma, tumour cells often experience low glutamine levels, which promote cell dedifferentiation. Here, we show that dietary glutamine supplementation significantly inhibits melanoma tumour growth, prolongs survival in a transgenic melanoma mouse model, and increases sensitivity to a BRAF inhibitor. Metabolomic analysis reveals that dietary uptake of glutamine effectively increases the concentration of glutamine in tumours and its downstream metabolite, αKG, without increasing biosynthetic intermediates necessary for cell proliferation. Mechanistically, we find that glutamine supplementation uniformly alters the transcriptome in tumours. Our data further demonstrate that increase in intra-tumoural αKG concentration drives hypomethylation of H3K4me3, thereby suppressing epigenetically-activated oncogenic pathways in melanoma. Therefore, our findings provide evidence that glutamine supplementation can serve as a potential dietary intervention to block melanoma tumour growth and sensitize tumours to targeted therapy via epigenetic reprogramming.


  • α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer

    by Thai Q. Tran, Eric A. Hanse, Amber N. Habowski, Haiqing Li, Mari B. Ishak Gabra, Ying Yang, Xazmin H. Lowman, Amelia M. Ooi, Shu Y. Liao, Robert A. Edwards, et al.

    Genetic-driven deregulation of the Wnt pathway is crucial but not sufficient for colorectal cancer (CRC) tumorigenesis. Here, we show that environmental glutamine restriction further augments Wnt signaling in APC-mutant intestinal organoids to promote stemness, and leads to adenocarcinoma formation in vivo via decreasing intracellular α-ketoglutarate (αKG) levels. αKG supplementation is sufficient to rescue low-glutamine-induced stemness and Wnt hyperactivation. Mechanistically, we found that αKG promotes hypomethylation of DNA and histone H3K4me3, leading to an upregulation of differentiation-associated genes and downregulation of Wnt target genes, respectively. Using organoids derived from patients with CRC and several in vivo CRC tumor models, we show that αKG supplementation suppresses Wnt signaling and promotes cellular differentiation, thereby significantly restricting tumor growth and extending survival. Together, our results reveal how the metabolic microenvironment impacts Wnt signaling and identify αKG as a potent antineoplastic metabolite for potential differentiation therapy for patients with CRC.